# Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction

> **NCT04944706** · PHASE2 · COMPLETED · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 225 (actual)

## Conditions studied

- Chronic Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time
- **DRUG:** Qishen Yiqi dripping pills 4 bags/time
- **DRUG:** Qishen Yiqi dripping pills placebo 4 bags/time

## Key facts

- **NCT ID:** NCT04944706
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-27
- **Primary completion:** 2024-12-19
- **Final completion:** 2024-12-19
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04944706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04944706, "Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04944706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*